Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

Article  PubMed  Google Scholar 

Kadys A, Gremke N, Schnetter L, Kostev K, Kalder M. Intercontinental comparison of women with breast cancer treated by oncologists in Europe, Asia, and Latin America: a retrospective study of 99,571 patients. J Cancer Res Clin Oncol. 2023;149(10):7319–26.

Article  PubMed  PubMed Central  Google Scholar 

Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, et al. Early breast cancer: ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2019;30(8):1194–220.

Article  PubMed  CAS  Google Scholar 

Ferreira Almeida C, Correia-da-Silva G, Teixeira N, Amaral C. Influence of tumor microenvironment on the different breast cancer subtypes and applied therapies. Biochem Pharmacol. 2024;223:116178.

Article  PubMed  CAS  Google Scholar 

Pietras K, Sjölund J. Cellular plasticity in the breast cancer ecosystem. Ups J Med Sci. 2024;129:e10629. https://doi.org/10.48101/ujms.v129.10629.

Article  Google Scholar 

Lin C-P, Chou Sh -H, Lin Y-S, Chiang H-Y, Yang Ch -K, Lin Y-S et al. The association between acute myocardial infarction and subsequent diagnosis of breast cancer: a nationwide, population-based cohort study. Sci Rep. 2024 Jul 9;14(1):15805. https://doi.org/10.1038/s41598-024-66141-7.

Berger ER, Iyengar NM. Obesity and energy balance considerations in triple negative breast cancer. Cancer J. 2021;27(1):17–24.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Clinical Guidelines on the. Identification, evaluation, and treatment of overweight and obesity in adults. The evidence report. Natl Institutes Health Obes Res. 1998; 6 Suppl 2: 51S–209S.

Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults 1999–2010. JAMA. 2012;307:491–7.

Article  PubMed  Google Scholar 

Argolo DF, Hudis CA, Iyengar NM. The impact of obesity on breast Cancer. Curr Oncol Rep. 2018;20:47.

Article  PubMed  Google Scholar 

Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371:569–78.

Article  PubMed  Google Scholar 

Iyengar NM, Hudis CA, Dannenberg AJ. Obesity and inflammation: new insights into breast cancer development and progression. Am Soc Clin Oncol Educ Book. 2013:33:46-51. https://doi.org/10.14694/EdBook_AM.2013.33.46.

Yoon HH, Lewis MA, Shi Q, Khan M, Cassivi SD, Diasio RB, et al. Prognostic impact of body mass index stratified by smoking status in patients with esophageal adenocarcinoma. J Clin Oncology: Official J Am Soc Clin Oncol. 2011;29:4561–7.

Article  Google Scholar 

Petrelli JM, Calle EE, Rodriguez C, Thun MJ. Body mass index, height, and postmenopausal breast cancer mortality in a prospective cohort of US women. Cancer Causes Control. 2002;13:325–32.

Article  PubMed  Google Scholar 

Kroenke CH, Chen WY, Rosner B, Holmes MD. Weight, weight gain, and survival after breast cancer diagnosis. J Clin Oncology: Official J Am Soc Clin Oncol. 2005;23:1370–8.

Article  Google Scholar 

Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, et al. Body fatness and Cancer–viewpoint of the IARC Working Group. N Engl J Med. 2016;375:794–8.

Article  PubMed  PubMed Central  Google Scholar 

Tezze C, Romanello V, Sandri M. FGF21 as Modulator of Metabolism in Health and Disease. Front Physiol . 2019 Apr 17:10:419. https://doi.org/10.3389/fphys.2019.00419. eCollection 2019.

Article  PubMed  PubMed Central  Google Scholar 

Luo Y, Ye S, Chen X, Gong F, Lu W, Li X. Cytokine Growth Factor Rev. 2017;38:59–65.

Article  PubMed  CAS  Google Scholar 

Berti L, Hartwig S, Irmler M, Radle B, Siegel-Axel D, Beckers J, et al. Impact of fibroblast growth factor 21 on the secretome of human perivascular preadipocytes and adipocytes: a targeted proteomics approach. Arch Physiol Biochem. 2016;122(5):281–8.

Article  PubMed  CAS  Google Scholar 

Inagaki T, Dutchak P, Zhao G, Ding X, Gautron L, Parameswara V, et al. Endocrine regulation of the Fasting response by PPARα-Mediated Induction of Fibroblast Growth Factor 21. Cell Metab. 2007;5(6):415–25.

Article  PubMed  CAS  Google Scholar 

Yasuhiro I, Bina HA, Noriyuki O, Akasaki Y, Kharitonenkov A, Kenneth W. FGF21 is an akt-regulated myokine. FEBS Lett. 2008;582(27):3805–10.

Article  Google Scholar 

Yue S, Chen J. Hepatic FGF21: its emerging role in inter-organ crosstalk and cancers. Int J Biol Sci. 2022;18(15):5928–42.

Article  Google Scholar 

Wang F, So K-F. Organ-organ communication. liver´s Perspective. 2021;11(7):3317–30.

CAS  Google Scholar 

McCarty MF. GCN2 and FGF21 are likely mediators of the protection from cancer, autoimmunity, obesity, and diabetes afforded by vegan diets. Med Hypotheses. 2014;83:365–71.

Article  PubMed  CAS  Google Scholar 

Luo Y, Yang C, Ye M, Jin C, Abbruzzese JL, Lee M-H, et al. Deficiency of metabolic regulator FGFR4 delays breast cancer progression through systemic and microenvironmental metabolic alterations. Cancer Metab. 2013;1(1):21.

Article  PubMed  PubMed Central  Google Scholar 

Degirolamo C, Sabba C, Moschetta A. Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23. Nat Rev Drug Discov. 2016;15:51–69.

Article  PubMed  CAS  Google Scholar 

Huang X, Yu C, Jin C, Kobayashi M, Bowles CA, Wang F, et al. Ectopic activity of fibroblast growth factor receptor 1 in Hepatocytes accelerates Hepatocarcinogenesis by driving proliferation and vascular endothelial growth factor–Induced Angiogenesis. Cancer Res. 2006;66:1481–90.

Article  PubMed  CAS  Google Scholar 

Yang C, Lu W, Lin T, You P, Ye M, Huang Y, et al. Activation of liver FGF21 in hepatocarcinogenesis and during hepatic stress. BMC Gastroenterol. 2013;13:67.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Knott ME, Minatta JN, Roulet L, Gueglio G, Pasik L, Ranuncolo SM et al. Circulating Fibroblast Growth Factor 21 (Fgf21) as Diagnostic and Prognostic Biomarker in Renal Cancer. Journal of molecular biomarkers & diagnosis. 2016; Suppl 2: 1.

Akyol M, Alacacioglu A, Demir L, Kucukzeybek Y, Yildiz Y, Gumus Z, et al. The alterations of serum FGF-21 levels, metabolic and body composition in early breast cancer patients receiving adjuvant endocrine therapy. Cancer Biomark A. 2017;18:441–9.

Article  CAS  Google Scholar 

Kang YE, Kim JT, Lim MA, Oh C, Liu L, Jung S-N, et al. Association between Circulating Fibroblast Growth Factor 21 and aggressiveness in thyroid Cancer. Cancers. 2019;11(8):1154.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Florea A, Harris RB, Klimentidis YC, Kohler LN, Jurutka PW, Jacobs ET. Circulating fibroblast growth Factor-21 and risk of Metachronous Colorectal Adenoma. J Gastrointest Cancer. 2021;52:940–6.

Article  PubMed  CAS  Google Scholar 

Cornier M-A. A review of current guidelines for the treatment of obesity. Am J Manag Care. 2022;28(15 Suppl):S288–96.

PubMed  Google Scholar 

Yu X, Li Y, Jiang G, Fang J, You Z, Shao G, et al. FGF21 promotes non-small cell lung cancer progression by SIRT1/PI3K/AKT signaling. Life Sci. 2021;269:118875.

Article  PubMed  CAS  Google Scholar 

Fletcher RH, Fletcher SW, Wagner EH. Clinical epidemiology: the essentials. 2nd ed. Baltimore, MD: Williams and Wilkins; 1988.

Google Scholar 

Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ, et al. FGF-21 as a novel metabolic regulator. J Clin Invest. 2005;115(6):1627–35.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Nishimura T, Nakatake Y, Konishi M, Itoh N. Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim Biophys Acta. 2000;1492(1):203–6.

Article  PubMed